Login / Signup

Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.

Aaron Y LeeThomas ButtEmily ChewElvira AgronTraci E ClemonsCatherine A EganCecilia Sungmin LeeAdnan Tufailnull null
Published in: The British journal of ophthalmology (2017)
The recommendation to publicly fund AREDS supplements to category 3 patients would depend on the healthcare system willingness to pay. In contrast, initiating AREDS supplements in AREDS category 4 patients is both cost saving and more effective than no supplement use and should therefore be considered in public health policy.
Keyphrases